Publicaciones en colaboración con investigadores/as de Instituto Cajal (33)

2023

  1. Programming of neural progenitors of the adult subependymal zone towards a glutamatergic neuron lineage by neurogenin 2

    Stem Cell Reports, Vol. 18, Núm. 12, pp. 2418-2433

2021

  1. Bcl-2-Assisted Reprogramming of Mouse Astrocytes and Human Fibroblasts into Induced Neurons

    Methods in Molecular Biology (Humana Press Inc.), pp. 57-71

2019

  1. Astrocytic p38α MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Synapse-specific regulation revealed at single synapses is concealed when recording multiple synapses

    Frontiers in Cellular Neuroscience, Vol. 11

  2. The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

    Journal of Psychiatry and Neuroscience, Vol. 42, Núm. 1, pp. 59-69

2016

  1. ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy

    Frontiers in Neuroscience, Vol. 10, Núm. JUN

  2. Activity-dependent switch of gabaergic inhibition into glutamatergic excitation in astrocyte-neuron networks

    eLife, Vol. 5, Núm. DECEMBER2016

  3. Vascular dysfunction in a transgenic model of Alzheimer's disease: Effects of CB1R and CB2R cannabinoid agonists

    Frontiers in Neuroscience, Vol. 10, Núm. SEP

2015

  1. Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[18F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke

    European Journal of Medicinal Chemistry, Vol. 101, pp. 604-615

2014

  1. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 80, pp. 543-561

  2. The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 2, pp. 235-246

2013

  1. Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: Implications for the pathogenesis of free radical-induced neurodegenerative disorders

    Psychopharmacology, Vol. 230, Núm. 1, pp. 125-135

  2. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

    Journal of Neuroscience, Vol. 33, Núm. 9, pp. 3953-3966

2012

  1. Dopamine D 1 receptor deletion strongly reduces neurotoxic effects of methamphetamine

    Neurobiology of Disease, Vol. 45, Núm. 2, pp. 810-820

2011

  1. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA

    Neurobiology of Disease, Vol. 42, Núm. 3, pp. 391-403

2010

  1. Lack of adrenomedullin, but not complement factor H, results in larger infarct size and more extensive brain damage in a focal ischemia model

    Neuroscience, Vol. 171, Núm. 3, pp. 885-892

  2. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.

    Neurotoxicity research, Vol. 18, Núm. 1, pp. 48-58

2009

  1. Ca2+/calmodulin-dependent kinase II signalling cascade mediates P2X7 receptor-dependent inhibition of neuritogenesis in neuroblastoma cells

    FEBS Journal, Vol. 276, Núm. 18, pp. 5307-5325

  2. The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone

    Schizophrenia Research, Vol. 115, Núm. 2-3, pp. 215-221

2008

  1. Early loss of dopaminergic terminals in striosomes after MDMA administration to mice

    Synapse, Vol. 62, Núm. 1, pp. 80-84